Article

A Podcast with Otis Brawley

Recently I reviewed Otis Brawley's provocative book, How We Do Harm: A Doctor Breaks Rank About Being Sick in America. In the book, Brawley, the chief medical and scientific officer of the American Cancer Society (and a member of CURE's scientific advisory board), takes issue with how the American healthcare system often provides far too much or far too little healthcare, and reveals how neither is good when it comes to treating cancer. You can read the full review here. Last Sunday, Joe and Terry Graedon of The People's Pharmacy interviewed Brawley about his book as well as his thoughts on various cancer screening methods, including the PSA test for prostate cancer and the spiral CT scans for lung cancer. The often skeptical Brawley digs deeper into these tests and provides context for the statistics, as well as his own advice on what patients should do when confronted with what has become a very confusing topic. To be sure, this hour-long podcast entitled The Underbelly of Healthcare (available here) is worth a listen and is free for four weeks following its August 25 release. After that, a digital download is available for $2.99.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Image of doctor with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.